"In approving this new whistle-blower rule, the S.E.C. has chosen to put trial lawyer profits ahead of effective compliance and corporate governance," David Hirschmann, president and chief executive of the Chamber's Center for Capital Markets Competitiveness, said at the time.
In the Utrecht Primary care P ROactive Frailty Intervention Trial (U-PROFIT), the effectiveness of the U-PRIM intervention, alone and in combination with U-CARE, will be assessed in comparison to usual care.
This PROFIT trial is designed as an RCT.
In this trial patients did profit from an early avoidance of Tacrolimus with regards to renal function [ 18].
In contrast with our hypothesis, we did not find that trials sponsored by for profit organisations or trials that recommended the experimental intervention were more likely to report inadequately on surrogates.
Drug companies would not foot the bill for such a trial because the profits to be made are small.
The U-PROFIT trial was designed to evaluate the effectiveness of these interventions.
In this paper, we present the research design and methodology of the U-PROFIT trial.
We met several challenges during the design and implementation of the U-PROFIT trial.
The aim of this paper is to describe the U-PROFIT trial design and to discuss methodological issues and challenges.
